Compare Amgen, Inc. (AMGN) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs KKR & Co Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while KKR & Co Inc trades at $96.68 (market cap $87.04B). The key difference: Amgen, Inc. is far larger — about 2.3× KKR & Co Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | KKR | |
|---|---|---|
Market Cap | $196.12B | $87.04B |
Sector | Health | Financials |
52-Week High | $388.16 | $152.16 |
52-Week Low | $271.18 | $83.88 |
Enterprise Value | $241.41B | $12.56B |
Dividend Yield | 2.77% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KKR trades at $96.94, up 0.7% today, with a bullish technical outlook supported by moving averages and near-term resistance at $97. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic acquisitions like the $4.2 billion EDF power solutions deal and a $1.3 billion renewable energy platform in South Korea. Strong analyst sentiment includes 24 buy ratings and a consensus price target of $127.71, indicating significant upside potential.
The outlook for KKR is positive, driven by robust monetization activity, strategic growth initiatives, and a favorable analyst consensus. Key risks include volatile cash flows from operations, high leverage with long-term debt of $49.91 billion, and dependence on private market conditions. Investors should weigh the growth opportunities against these financial and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
